BCRX Key Statistics, Chart & Performance
The current stock price of BCRX is 7.17 USD. In the past month the price decreased by -4.02%. In the past year, price decreased by -3.76%.
BCRX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BCRX. When comparing the yearly performance of all stocks, BCRX turns out to be only a medium performer in the overall market: it outperformed 46.58% of all stocks.
BCRX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BCRX. BCRX has a medium profitability rating, but doesn't score so well on its financial health evaluation.
BCRX Financial Highlights
Over the last trailing twelve months BCRX reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS increased by 94.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.97% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BCRX Forecast & Estimates
15 analysts have analysed BCRX and the average price target is 21.23 USD. This implies a price increase of 196.16% is expected in the next year compared to the current price of 7.17.
For the next year, analysts expect an EPS growth of 139.32% and a revenue growth 37.52% for BCRX
BCRX Ownership
BCRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.94 | 383.08B | ||
| AMGN | AMGEN INC | 15.09 | 177.71B | ||
| GILD | GILEAD SCIENCES INC | 14.81 | 150.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.28 | 111.36B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.48 | 77.98B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.43 | 47.46B | ||
| INSM | INSMED INC | N/A | 33.97B | ||
| NTRA | NATERA INC | N/A | 33.17B | ||
| BIIB | BIOGEN INC | 10.07 | 24.73B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.83B | ||
| INCY | INCYTE CORP | 16.39 | 20.66B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.89 | 20.32B |
Related stock screener links
About BCRX
Company Profile
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The company is headquartered in Durham, North Carolina and currently employs 580 full-time employees. The firm leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
Company Info
BIOCRYST PHARMACEUTICALS INC
4505 Emperor Blvd Ste 200
Durham NORTH CAROLINA 27703 US
CEO: Jon P. Stonehouse
Employees: 580
Phone: 19198591302
BIOCRYST PHARMACEUTICALS INC / BCRX FAQ
Can you describe the business of BIOCRYST PHARMACEUTICALS INC?
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The company is headquartered in Durham, North Carolina and currently employs 580 full-time employees. The firm leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
What is the current price of BCRX stock?
The current stock price of BCRX is 7.17 USD. The price increased by 5.75% in the last trading session.
Does BIOCRYST PHARMACEUTICALS INC pay dividends?
BCRX does not pay a dividend.
How is the ChartMill rating for BIOCRYST PHARMACEUTICALS INC?
BCRX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the analyst forecast for BCRX stock?
15 analysts have analysed BCRX and the average price target is 21.23 USD. This implies a price increase of 196.16% is expected in the next year compared to the current price of 7.17.
What is the market capitalization of BCRX stock?
BIOCRYST PHARMACEUTICALS INC (BCRX) has a market capitalization of 1.51B USD. This makes BCRX a Small Cap stock.
Can you provide the ownership details for BCRX stock?
You can find the ownership structure of BIOCRYST PHARMACEUTICALS INC (BCRX) on the Ownership tab.